Medical Manager

FRED WANG, MD EMBA

**** ******* ***** ****

Lake Zurich, IL, USA 60047

abm2eb@r.postjobfree.com

VP biopharm Global

Business Bridge, Inc

Tel. 847-***-****,

GLOBAL R&D, STEM CELL

MEDICAL AFFAIRES AND MANAGEMENT

PROFILE: ? Comprehensive experience in medical affaire / practice,

R&D, direction and administration of novel product

development, from concept to completion in clinical

studies / biotech business, industrialization and

commercialization of medical products, stem cell/biotech as

R&D manager, head, hospital VP and bio-pharmaceutical/ stem

cell company Director, GM, CEO and president.

? Intensive stem cell research and clinical application

experiences in hospital, bio- pharmaceutical company,

university and National Cell Product Center in China, Japan

and USA (16 years). Broad international connection for

stem cell novel clinical application,created the stem cell

company from very beginning to its fully operation,

including research lab, GMP facility, Clinical research and

application.

? Proficient in strategic planning and administration of new

drug development including R&D, pre-clinical study,

and clinical investigation; design, organize and

negotiate international studies in Asia, North / South America, and

Europe.

? Education in medicine and management (EMBA). Proven

abilities to create and manage new research projects and

business. clinical medicine, cellular biology training and

experiences in Loma Linda University, Amgen and National

Academy Science USAMRIID of America, Plan and conduct

international presentation in more than fourteen countries

and regions, skilled in patent, and paper publication.

? Familiar with modern basic and clinical medical science,

formal medical and post-graduate medical education,

clinical practice in internal medicine, expertise in key

clinical fields, Instruct and coach scientists, medical

student and clinicians in research in university and bio-

pharm industries

? Extensive knowledge, experience and well trained in bio-

pharmaceutical industries for medical research and clinical

trials, certificated in Clinical Trial Administration; GLP;

Advanced GCP / ICH and FDA; and Clinical Trial Contract

Negotiation

? My research include new drug discovery, development, cell

therapy (hematopoietic stem cell, mesenchymal stem cell and

component cell therapy in research and clinical

application), stem cell research and regeneration medicine,

which include statistical analysis, grant writing, and

knowledge of bio-safety regulations

EXPERIENCE:

VP Biopharmaceutical Center. Chief / General Manager

Management, international business and new drug development, it

includes:

? New Bio-Pharmaceutical R&D center

? Clinical trial centers for diverse pharmaceutical products

? Asia-Pacific hematology/oncology and cardiovascular drug

research Center

? Global Business Development and outsourcing service for

major international companies, pre-clinical study and

clinical trials

Global Business Bridge, Inc. Bio President, 2007-now

Overall management for the company with focusing on

the promotion of Chinese

Bio-pharmaceutical and stem cell business, global financial

and business service

AmCellGene Inc. and National Engineering Center of

Cell Products CEO 2005-2006

Created the stem cell company and National Cell Product center

from very beginning to its fully operation, including research

lab, GMP facility, Clinical research and application. Oversee

and manage all aspects in the center and company, leading novel

drugs, stem cell research & development, stem cell clinical

application, building up the GMP facilities, making

international communication, business development, setting up

clinical trial, marketing and hospital collaboration.

Sysmex America Inc. Long Gove / Mundelein, IL USA /

SCJ, Kobe, Japan

Head, R&D / Principal Scientist

2001-2005

Global business development and marketing, Medical affairs and

International R&D, new product development,

? New business development; administration, negotiation, and

contract of International Clinical Research on Stem Cells

and medical instrument with sites in North/South America,

Asia, and Europe.

? Medical and scientific market presentations at

international conferences and company organized seminars in

China -Taiwan, Hong Kong America, Japan,,, UK, Canada,

Malaysia, Philippine, Brazil, Belgium, Germany, Spain and

France.

? Research & development, medical instrumentation, budget,

and patent of useful clinical technology and biotech

products, projects including Stem Cells, Apoptosis,

hematopoiesis and cellular therapy, working with FDA for

new product application.

Loma Linda University Medical School, Loma Linda, CA USA

Senior Scientist / Manager 1995-2001

Manage basic and clinical research, international presentation

for marketing

? Basic and clinical researches for medical application

? Stem cell biology, application, hematology with molecular

and cellular biology

? Supervise and train technical staffs in the laboratory,

instruct clinician,

post-doctors, and graduate students.

? Management of the research projects, accomplishment with

new contract, patents, products, publications and global

presentations for new business development

AMGEN, Thousand Oaks, CA USA

Research Scientist 1991-1995

? Bio-pharmaceutical research for new drug development

including pre- clinical studies,Stem cell biology and

application

? New drug research and development with cellular /

molecular biology and animal model and clinical investigation

? Discovery of novel growth factors such as thrombopoietin

(TPO) with cell culture, flow cytometer and animal model

USAMRIID, National Research Council (NRC) of USA, Frederick, MD

Senior Post-Doctoral Investigator 1989-

1991

? Investigation on hemorrhage mechanism in infectious

disorders

? Platelet function and coagulation / anti-coagulation,

thrombosis studies

? Bleeding mechanisms in hemorrhage fever diseases with

multi-methods

PLA Postgraduate Medical School and General Hospital Physician

? Clinical practice in internal medicine focusing on

hematology /oncology

? Role of SJSAMP, Urokinase, and other enzymes on the

thrombosis, platelet function and plasma proteins

? Laboratory medical researches

Tianjin Hexi Hospital and Hematology Institute physician, VP

? Administration and management of clinical research and

medical affairs as

Hospital VP; also taking care of all type patients with

blood disorders

? Clinical practice in internal medicine, focusing on

hematology /oncology

? Cell therapy and new drug clinical trials

? Novel drug clinical application and bone marrow

transplantation

EDUCATION:

Main

? Tianjin Medical University, Tianjin (Clinical

Medicine)

? PLA Post-graduated Medical School, Beijing

(Hematology)

? Tsinghua University / Phoenix International

University (EMBA)

? Medical Department, USAMRIID, National Research

Council of America,

Frederick, Maryland, USA (Senior Post-Doctor Award)

Others

? Clinical Trial Administration, and GLP, University of

California, San Diego

USA

? Advanced Good Clinical Practice

(GCP) by Pharmaceutical Education

& Research Institute, USA (Certification)

? Clinical Research Contract Professional, MAGI, USA

(Certification)

MEMBERSHIP:

? Drug Information Association (DIA)

? International Society of Cell Therapy (ISCT)

? Association of Clinical Research Professionals (ACRP)

? Clinical Trial Model Agreement Group Initiative (MAGI)

? American Society of Hematology (ASH)

? International Society of Experimental Hematology (ISEH)

? Clinical Flow Cytometer Association (CFCA)

? International Society of Thrombosis and Hemostasis (ISTH)

? American Association of Blood Banks (AABB)

? American Association for the Advancement of Science (AAAS)

PATENT:

? FIC for Apoptosis, USA, US patent # 5,804,448

? Stem Cell and Progenitor Cells, USA, US patent # 5,830,701

? NRBC QC and clinical application, USA, US patent #

6,448,085

? Reticulated platelet fraction and clinical application,

USA

? Nucleated Red Blood Cells (NRBC). USA and Japan

? CD34 negative Hematopoietic Stem Cell and clinical

application, USA

? Megakaryocyte and clinical application, USA

? New stem cell patent in China

Publications and International Presentations

1. Wang FS: Current stem cell therapy and potential future clinical

application of HPC program. Mundelein IL USA January, 2005

2. Wang FS, Rowan RM, Creer M, et, al: Detecting Human CD34+ and CD34-

Hematopoietic Stem and Progenitor Cells Using an Automated Hematology

Analyzer. 10(4):200, 2004

3. Wang FS: Reticulated Platelet and IPF in clinical application.

Presented in Japan, Europe and China, 2004

4. Wang FS and Trester C: Bone marrow cell and myocardial regeneration.

International Journal Hematology. 79:322, 2004

5. Wang FS and Kershaw J: Modern Biomedical Sciences and Hematology

Instrumentation. Sysmex Journal International 13(1): 1, 2003

6. Wang FS Megakaryocyte testing with automated hematology analyzer, XE-

2100. ISEH meeting, Paris, France, July, 2003

7. Wang FS, et al: Preliminary Investigation of CD34 Negative

Hematopoietic Stem Cells on the Automated Hematology Analyzer. Blood

100(11): 147b. 2002

8. Wang FS, et al: Development and clinical application of nucleated red

blood cell counting and staging on the automated haematology analyzer

XE-2100. Clin. Lab. Haem. 13:17-23, 2003

9. Wang FS, et al: Monitoring Hematopoietic stem and progenitor Cells

with Sysmex Automated Hematology Analyzers. Lab. Hematol 8:119-125,

2002

10. Wang FS and Kubota F: A Novel Apoptosis Research Method with Imaging-

Combined Flow Cytometer and HITC or IR-125 staining. Clinical

Cytometry 50:267-***-****

11. Wang FS: CD34 Negative Hematopoietic Stem Cells. 12:1-8, 2002 Sysmex J

International

12. Wang FS The investigation of the clinical applications of NRBC

counting, staging and quality control on the XE-2100 automated

hematology analyzer. Montpillier, France, May 2001the XIVth

International Symposium on Technological Innovations in laboratory

Hematology. Montpillier, France, May 2001

13. Wang FS: New parameters on automated hematology analyzer and their

clinical applications. The international congress on laboratory

medicine in the 21th century, Taipei Taiwan, April, 2001

14. Wang FS NRBC quality control and calibrator on XE-2100 hematology

analyzer. Presented on the XIVth International Symposium on

Technological Innovations in laboratory Hematology. Montpillier,

France, May 2001the XIVth International Symposium on Technological

Innovations in laboratory Hematology. Montpillier, France, May 2001

15. Wang FS, et al: Development and clinical application of nucleated red

blood cell staging with hematology analyzer XE-2100. Lab Hematol

1:33, 2000

16. Wang FS, et al: Apoptosis observation with Sysmex R-3000 hematology

analyzer, ISLH, 1999

17. Xu ZH, Ju GD, Wang JM, and Wang FS: Observation on the treatment

effect of the long-term survival of adult patients with ANLL by

intermediate-dose of ARA-C. Blood Supplement 92:220b, 1998.

18. Wang QS, Lin XP, and Wang FS: A case-control study of leukemia in

young people in Tianjin, People's Republic of China. Blood Supplement

92:214b, 1998

19. Wang FS, Kubota B, North M, Hagbloom R, Mast B, Stewart N, Begg KA,

Iwata T, Nakamoto H, Houwen B: Development of a novel apoptosis

research method with flow image cytometer-FIC and HITC or IR-125.

Blood Supplement 92:167b, 1998

20. Wang FS, Kubota B, Hagbloom R, Mast B, Stewart N, Iwata T, Nakamoto H,

Houwen B: Physiological regulation of thrombopoiesis determined with

automatic cell analyzer. Blood Supplement 92:91b, 1998

21. Wang FS, Tsuji T, Sakata T, Hamaguchi Y, Hagbloom R, Houwen B:

Counting and staging of peripheral and cord blood nucleated red blood

cells by flow cytometry. Lab Hematol 1:96, 1998. Orally presented on

the XIIth international Symposium of technological Innovations in

Laboratory Hematology. Banff, Canada, 1998

22. Tsuji T, Sakata T, Hamaguchi Y, and Wang FS, Houwen B: A new flow

cytometric method for the nucleated red blood cell count. Lab Hematol

1:109, 1998.

23. Wang FS, Houwen B: Apoptosis in Clinical Hematology. Sysmex J

International. 7:1, 1997

24. Wang FS, Kubota B, North M, Hagbloom R, Mast BJ, Stewart N, Kathryn

AB, Iwata T, Nakamoto H, Houwen B: A novel apoptosis research method

with Flow Image Cytometer-2 (FIC-2) and HITC or IR-125 staining.

Orally presented on the Xth International Symposium of technological

Innovations in Laboratory Hematology, Brugge, Belgium, 1997

25. Houwen B, Stewart N, Wang FS: Human progenitor cell (HPC)

identification in patients undergoing stem cell mobilization, using a

routine hematology analyzer. Lab Hematol 2:166, 1997

26. Wang FS, Houwen B: Reticulated platelet measurement and clinical

application. submitted for publication, 2000

27. Wang FS, Kubota B, North M, Hagbloom, Mast BJ, Stewart N, Iwata T,

Nakamoto H, Houwen B: Apoptotic HL-60 cells induced with camptothecin

(CAM) and 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine (H7) provide

a model for flow imaging cytometry of apoptosis. Blood 88:123b, 1996

28. Houwen B, Bryner M, Hagbloom H, Mast BJ, Stewart N, and Wang FS:

Identification of young and immature platelets as indicators for bone

marrow recovery. Lab Hematol 2:76, 1996 and presented on Keystone

Symposium on Thrombopoiesis, Taos, NM 1996

29. Houwen B, Wang FS, Stewart N: Detection of abnormal, immature and

hematopoietic stem cells on the Sysmex SE-9000: a new frontier. ISH

meeting workshop, Brisbane, Australia and ADC Workshop, Sydney,

Australia, 1995

30. Houwen B, Wang FS, Mast BJ, Stewart N, Hagbloom R: Definition of RNA-

poor platelet populations. Blood 88:319a, 1996

31. Wang FS, Brathwaite, Hagbloom R, Mast BJ, Stewart N, Houwen B: Effect

of incubation time and temperature on apoptosis occurring in vitro in

human peripheral blood. Blood 88:124b, 1996

32. Houwen B, Wang FS, Stewart N: Screening for hematopoietic stem cells

by the Sysmex SE-9000 hematology analyzer. Blood 88:235b,1996

33. Houwen B, Wang FS, Stewart N: The timing of peripheral blood stem cell

harvests: Screening for hematopoietic stem cells on the SE-9000. Lab

Hematol 2:51, 1996

34. Wang FS, et al: Behavior of Purified CD34 positive cells on the

automated hematology analyzer. Loma Linda University Medical School

Round Table Symposia, 1995

35. Wang FS, Cosgriff TM et al: Effects of an attenuated strain of Junin

virus on production of coagulant and anticoagulant proteins by Hep G2

cells. Presented on the American Society of Hematology 33rd Annual

meeting. Blood 82: 600, 1993

36. Wang FS, Cosgriff TM et al: Effects of cytokines on the protein C and

protein S concentration from Hep G2 cell culture, presented on the

International Society of Hematology 23rd congress and the American

Society of Hematology 32nd annual meeting. Blood 76:442a, 1990

37. Wang FS, Li CF et al: Platelet aggregation induced by SJSAMP needs

calcium, magnesium and normal calcium flux. Thrombosis and Hemostasis

65:1106, 1991

38. Wang FS, Li CF et al: First case report of platelet thromboxane

synthetase deficiency in China. Thrombosis and Hemostasis 65:1324,

1991

39. Wang FS, Li CF et al: Effects of urokinase on plasma protein and

coagulation. Blood 76:442a, 1990

40. Wang FS, Li CF et al: Effects of different inhibitors on platelet

aggregation induced by Stichopus Japonicas Selenka Acid

Mucopolysaccharide. Blood 74:406a, 1989

41. Wang FS, Ju GD et al: Treatment of acute refractory lymphocytic

leukemia with high dose methotrexate. Tianjin Med J 12:434, 1984

42. Wang FS, Wang JM et al: Observation of 16 cases of acute promyelocytic

leukemia. Second National conference of Hematology. Luoyang, 1984

43. Wang FS: High dose chemotherapy of leukemia (review). International

Medicine-Internal Medicine 11:534, 1984

Contact this candidate